Department of Microbiology and Immunology, University of Western Ontario, London, ON, N6A 5C1, Canada.
Imperial College London, Department of Infectious Diseases, Division of Medicine, Norfolk Place, London, W2 1PG, UK.
Viruses. 2018 Apr 1;10(4):167. doi: 10.3390/v10040167.
An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.
一种有效的 HIV-1 疫苗被认为是阻止当前 HIV-1 流行的最佳方法。然而，尽管在开发安全有效的疫苗方面做出了巨大努力，但 modestly protective RV144 试验仍然是唯一一项能提供一定程度的 HIV-1 感染保护的疗效试验。本文将概述 HIV 疫苗开发的历史、应用于 HIV 疫苗学和免疫原设计的新技术，以及正在进行的研究，以增进我们对疫苗诱导的保护免疫相关因素的理解。
